• Mashup Score: 2

    IntroductionEfforts to develop biomarker-targeted anti-cancer therapies have progressed rapidly in recent years. With efforts to expedite regulatory reviews of promising therapies, several targeted cancer therapies have been granted accelerated approval on the basis of evidence acquired in single-arm phase II clinical trials. And yet, in the absence of randomization, patient prognosis for…

    Tweet Tweets with this article
    • RT @n8pennell: Optimal predictive probability designs for randomized biomarker-guided oncology trials https://t.co/e5EnDRXiqp @zabormetrics

  • Mashup Score: 2

    IntroductionEfforts to develop biomarker-targeted anti-cancer therapies have progressed rapidly in recent years. With efforts to expedite regulatory reviews of promising therapies, several targeted cancer therapies have been granted accelerated approval on the basis of evidence acquired in single-arm phase II clinical trials. And yet, in the absence of randomization, patient prognosis for…

    Tweet Tweets with this article
    • Optimal predictive probability designs for randomized biomarker-guided oncology trials https://t.co/e5EnDRXiqp @zabormetrics